Aperçu rapide pour Th1/Th2 Cytokine Standard (ABIN1379792)
Antigène
IL-2, IL-4, IL-5, IL-6, IL-10, TNF, IFN-gamma
Application
Immunoassay (IA), Flow Cytometry (FACS)
Reactivité
Humain
Attributs du produit
The Human Th1/Th2 Cytokine Standard contains a mixture of individually lyophilized recombinant proteins made up of human Interleukin (IL)-2, IL-4, IL-5, IL-6, IL-10, Tumor Necrosis Factor (TNF), and Interferon-gamma (IFN-gamma). The reconstituted Human Th1/Th2 Cytokine Standard is designed for use as a standard control with the BD™ Cytometric Bead Array (CBA) Human Th1/Th2 Cytokine Kit (Cat. No. 550749 or 551809) and the BD™ Cytometric Bead Array (CBA) Non-Human Primate Th1/Th2 Cytokine Kit (Cat. No. 557800). Please refer to the manual included with these kits for further information
Restrictions
For Research Use only
Format
Lyophilized
Buffer
Lyophilized in an aqueous buffered solution containing BSA and ProClin™ 150.
Agent conservateur
ProClin
Précaution d'utilisation
This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Stock
4 °C
Stockage commentaire
Store the lyophilized standard at 4°C prior to reconstitution. Lyospheres from 1 vial of the Human Th1/Th2 Cytokine Standard, when reconstituted in 2.0 mL Assay Diluent, approximates the CBA activity of human IL-2, IL-4, IL-5, IL-6, IL-10, TNF, and IFN-γ at a concentration of 5000 pg/mL. Following reconstitution, maintain the Human Th1/Th2 Cytokine Standard at 4°C and use within 12 hours. Any unused reconstituted standard must be discarded after this period (do not store or reuse).
Cook, Stahl, Lowe, Chen, Morgan, Wilson, Varro, Chan, Graziano, Barney: "Simultaneous measurement of six cytokines in a single sample of human tears using microparticle-based flow cytometry: allergics vs. non-allergics." dans: Journal of immunological methods, Vol. 254, Issue 1-2, pp. 109-18, (2001) (PubMed).
Dotti, Savoldo, Takahashi, Goltsova, Brown, Rill, Rooney, Brenner: "Adenovector-induced expression of human-CD40-ligand (hCD40L) by multiple myeloma cells. A model for immunotherapy." dans: Experimental hematology, Vol. 29, Issue 8, pp. 952-61, (2001) (PubMed).